A practical transition-metal-free procedure for the synthesis of (E)-vinylsulfones through the coupling of vinylhalides with sodium sulfinates in water is reported. The reaction is strongly influenced by the presence of acids, and the use of nBu4NBr promotes its efficiency.
selective dehydrohalogenation to form alpha-haloacrylate analogues. A variety of alpha-halo Michael acceptors were prepared in dimethyl sulfoxide under mild, base-free conditions, including the preparation of alpha-bromoacrolein and alpha-chloro- and bromoacrylonitriles. Synthesis of these molecules has been reported in the literature to be difficult. Among all the existing dehydrohalogenation procedures
[EN] RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] AGENTS DE DÉGRADATION DE LA PROTÉINE RAS, COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI ET LEURS APPLICATIONS THÉRAPEUTIQUES
申请人:BIOTHERYX INC
公开号:WO2021051034A1
公开(公告)日:2021-03-18
Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-mediated disorder, disease, or condition.
Synthesis of Nitrogen‐Containing Goniothalamin Analogues with Higher Cytotoxic Activity and Selectivity against Cancer Cells
作者:Matheus A. Meirelles、Carolyne B. Braga、Catia Ornelas、Ronaldo A. Pilli
DOI:10.1002/cmdc.201900281
日期:2019.8.6
goniothalamin analogues displaying nitrogen‐containing groups were designed and synthesized. A total of 19 novelanalogues were evaluated against a panel of four different cancer cell lines, along with the normal prostate cell line PNT2 to determine their selectivity. Among them, goniothalamin chloroacrylamide 13 e displayed the lowest IC50 values for both MCF‐7 (0.5 μm) and PC3 (0.3 μm) cells, about 26‐fold
[EN] INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON ET LEURS PROCÉDÉS D'UTILISATION
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017100668A1
公开(公告)日:2017-06-15
The present disclosure is directed to compounds of formula I and methods of their use and preparation, as well as compositions comprising compounds of formula I.